# BrightGene Bio-Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brightgene-bio-medical-technology-co

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.bright-gene.com
- Latest round: Series A (Aug 22, 2014)
- Investors on record: 2

## About

Established in 2001 and based in Suzhou, China, BrightGene Bio-Medical Technology Co., Ltd. operates as an API and preparation developer that mainly provides original new drugs. In January 2019, it raised CNY 550 million of pre-IPO funding led by new investors HighLight Capital and Sequoia Capital. In November 2019, BrightGene Bio-Medical Technology Co., Ltd. was listed on the Shanghai Stock Exchange.

The company mainly provides API and preparation drugs. The product line covers multiple therapeutic areas such as antiviral, antifungal, immunosuppressive, anti-tumor, cardiovascular and cerebrovascular, respiratory, and iron supplements. Products include BGM0504 injection, entecavir, pimecrolimus, and micafungin sodium for injection.

The company generates revenue by providing API and preparation drugs such as BGM0504 injection and entecavir.

## Funding rounds

- Series A, Aug 22, 2014 — CS Capital, YuanBio Venture

## Investors

- CS Capital — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A